Pricing Log in Create free account
Friday 6 November 2026 Export AXSM’s income statement to Excel — free account

Axsome Therapeutics, Inc.

AXSM Healthcare Biotechnology

Axsome Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $638.5 million, up 65.5% from fiscal 2024.

Revenue
+51.9%
EPS
+73.9%
Free cash flow
−1,078.3%
Total debt
+4.04%

Quarter to September 2026, against a year earlier

132.13 2.33 +1.80%
Market cap
$6.8B
P/E
0.0×
Fwd P/E
−49.2×
Dividend yield
—
F-score
5/9
Altman Z
6.91
Beneish M
−2.53
Dividend safety
n/a
Overview Business Profile Earnings & Analysis
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios
Segments Valuation Filings

Axsome Therapeutics, Inc. (AXSM) SEC filings, changes and red flags

Red flags

Filings

Form Period Filed What it reports Flags
10-Q Sep 30, 2026 P1I2: 23 modified
P2I1A: no comparison — low extraction confidence
8-K Nov 2, 2026 2.02 Results of operations and financial condition; 8.01 Other events; 9.01 Financial statements and exhibits
10-Q Jun 30, 2026 P1I2: 3 added · 2 removed · 24 modified
P2I1A: no comparison — low extraction confidence 		Inventory outpacing revenue
8-K Aug 10, 2026 2.02 Results of operations and financial condition; 8.01 Other events; 9.01 Financial statements and exhibits
8-K Jul 15, 2026 8.01 Other events; 9.01 Financial statements and exhibits
8-K Jun 5, 2026 5.02 Departure or appointment of directors or officers; 9.01 Financial statements and exhibits Officer departure
8-K Jun 5, 2026 5.07 Submission of matters to a vote of security holders; 9.01 Financial statements and exhibits
8-K Jun 3, 2026 8.01 Other events; 9.01 Financial statements and exhibits
10-Q Mar 31, 2026
8-K May 4, 2026 2.02 Results of operations and financial condition; 8.01 Other events; 9.01 Financial statements and exhibits
8-K Apr 30, 2026 8.01 Other events; 9.01 Financial statements and exhibits
8-K Apr 1, 2026 8.01 Other events; 9.01 Financial statements and exhibits
10-K Dec 31, 2025 1: 31 added · 57 removed · 61 modified
1A: 22 added · 6 removed · 57 modified
7: 13 added · 21 removed · 29 modified
8-K Feb 23, 2026 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
8-K Feb 17, 2026 8.01 Other events; 9.01 Financial statements and exhibits
8-K Jan 12, 2026 2.02 Results of operations and financial condition; 8.01 Other events; 9.01 Financial statements and exhibits
8-K Dec 31, 2025 8.01 Other events; 9.01 Financial statements and exhibits
10-Q Sep 30, 2025
8-K Nov 3, 2025 2.02 Results of operations and financial condition; 8.01 Other events; 9.01 Financial statements and exhibits
10-Q Jun 30, 2025
8-K Aug 4, 2025 2.02 Results of operations and financial condition; 8.01 Other events; 9.01 Financial statements and exhibits
10-Q Mar 31, 2025
8-K May 5, 2025 2.02 Results of operations and financial condition; 8.01 Other events; 9.01 Financial statements and exhibits
10-K Dec 31, 2024
8-K Feb 18, 2025 2.02 Results of operations and financial condition; 8.01 Other events; 9.01 Financial statements and exhibits
8-K Jan 13, 2025 2.02 Results of operations and financial condition; 8.01 Other events; 9.01 Financial statements and exhibits
10-Q Sep 30, 2024
8-K Nov 12, 2024 2.02 Results of operations and financial condition; 8.01 Other events; 9.01 Financial statements and exhibits
10-Q Jun 30, 2024
8-K Aug 5, 2024 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
8-K May 6, 2024 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
8-K Feb 20, 2024 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
8-K Jan 4, 2024 2.02 Results of operations and financial condition; 8.01 Other events; 9.01 Financial statements and exhibits
8-K Nov 6, 2023 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits

From the company’s filings on sec.gov. Red flags are raised by rules over the filings’ own data and text; they are not investment advice.